Clinical trials
Breast Cancer Invasive clinical trials
Below are recruiting breast cancer invasive clinical trials, each written for real people, not researchers. We’re tracking 717 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05704829RecruitingPhase 2
Trastuzumab-deruxtecan before surgery for HER2-positive early breast cancer
This trial compares giving trastuzumab-deruxtecan before surgery versus standard chemotherapy plus trastuzumab and pertuzumab. It aims to see which approach works better to shrink or control HER2-positive early breast cancer and improve outcomes.
Baden-Baden, Baden-WurttembergAges 18 years+ - NCT07085442Recruiting
Audit of targeted lymph node biopsy for early breast cancer
This study looks at how well a special type of lymph node biopsy works for people with early breast cancer that has spread to a small number of lymph nodes. It aims to see if this approach is effective and safe, which may help guide future treatment decisions.
BurnleyAges 18 years+ - NCT03646955Recruiting
Partial breast radiation versus no radiation after lumpectomy
This trial compares giving radiation only to part of the breast versus not giving radiation at all after breast-conserving surgery. It’s meant for women with early, hormone-driven breast cancer to see if skipping radiation can be safe and reduce treatment burden.
SantiagoAges 60 years+ - NCT04937309Recruiting
Vagus nerve stimulation for nausea from chemo
This trial tests a non-invasive device that stimulates a nerve in your ear to help prevent nausea caused by chemotherapy. It is for people with breast cancer who are about to start a specific type of chemo (anthracycline and cyclophosphamide).
BloisAges 18 years+ - NCT05433753Recruiting
Study for leftover cancer DNA in HER2-positive early breast cancer
This study looks for tiny traces of cancer after treatment by testing blood for “ctDNA,” which is leftover cancer DNA. It includes people with HER2-positive early breast cancer who are getting chemotherapy before surgery to see if this blood test can detect signs of remaining disease.
Chuo-ku, TokyoAges 20 years+ - NCT05059444Recruiting
Blood test to catch cancer early after treatment
This study looks for signs of cancer left in the body after treatment using a simple blood test (called a liquid biopsy). It aims to see if the test can catch cancer that might come back earlier than regular scans.
Birmingham, AlabamaAges 18 years+ - NCT04333706RecruitingPhase 1/Phase 2
Sarilumab plus capecitabine for certain breast cancers
This trial studies whether adding sarilumab to capecitabine can shrink or control metastatic or high-risk breast cancer that lacks HER2 and is either triple-negative or hormone-resistant. It aims to find a safe dose first, then look at how well the treatment works compared with historical results.
Los Angeles, CaliforniaAges 18–99 - NCT06498154RecruitingPhase 2
Skipping breast surgery for some patients after chemo
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
TianjinAges 18–70 - NCT03643861Recruiting
Radiation after lumpectomy for certain early breast cancers
This trial tests a short, highly targeted radiation plan given in five sessions after lumpectomy for early-stage breast cancer. It may help treat the remaining breast area while aiming to limit exposure to healthy tissue.
Birmingham, AlabamaAges 18–99 - NCT04469296Recruiting
Diet changes before surgery for hormone-receptor breast cancer
This trial tests whether changing your diet before your breast surgery can help people with early, hormone-receptor (ER/PR+) breast cancer. It focuses on patients who have not started treatment yet and want to keep surgery as the main treatment.
Montpellier, HeraultAges 18–80 - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT03829553RecruitingPhase 3
Radiation to breast lymph nodes versus standard breast cancer care
This Phase 3 trial tests whether a shorter, more focused radiation treatment to the regional lymph nodes works as well as the current standard approach for certain breast cancers. It may help patients by potentially improving treatment efficiency while keeping cancer control effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05212454RecruitingPhase 3
Capecitabine added after surgery for high-risk ER-positive breast cancer
This Phase 3 study tests whether adding capecitabine (a chemotherapy pill) after breast cancer surgery can lower the chance the cancer comes back. It targets people with hormone-receptor–positive and HER2-negative breast cancer who are considered “high risk.”
Hanzhou, ZhejiangAges 18–70 - NCT07829848Recruiting
Skip extra radiation for breast cancer patients who respond well to treatment
This trial tests whether women and men with advanced, non-metastatic breast cancer can safely skip an extra radiation boost to the lymph nodes if their tumors respond well to pre-surgery chemotherapy or targeted therapy. The goal is to reduce side effects while keeping cancer control.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05635487RecruitingPhase 2
Neoadjuvant treatment for HER2-positive breast cancer with SHR-A1811
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
Shenyang, LiaoningAges 18–75 - NCT07753226RecruitingPhase 1
Study of SI-B036 for advanced breast cancer and other solid tumors
This study tests a new drug called SI-B036 for people with advanced breast cancer or other solid tumors that have spread. The goal is to see if the drug is safe and to find the best dose.
Beijing, Beijing MunicipalityAges 18–75 - NCT06171360Recruiting
Gut bacteria and CDK4/6 inhibitor treatment in breast cancer
This study looks at how gut bacteria affect response to a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy in breast cancer that is hormone receptor-positive and HER2-negative. It may help find out why some people respond better to treatment and could lead to better personalized care.
BrusselsAges 18–100 - NCT06642428Recruiting
Vitamin D for breast cancer treatment before surgery
This trial tests whether taking vitamin D pills during chemotherapy or targeted therapy (before breast cancer surgery) can improve how well the treatment works and reduce side effects. It is for women with low vitamin D levels.
Xining, QinghaiAges 18–80 - NCT07441460RecruitingPhase 3
KN026 plus HB1801 after surgery for HER2-positive breast cancer
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07340398RecruitingPhase 2
Testing new drug combos for HER2-positive breast cancer not responding to first therapy
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
HangzhouAges 18–75 - NCT07237256RecruitingPhase 3
Testing less chemo for HR+ HER2- breast cancer with ribociclib
This trial tests whether some people with hormone receptor-positive, HER2-negative early breast cancer can safely receive less chemotherapy when also taking the targeted drug ribociclib after surgery. You may qualify if you have a specific stage of breast cancer and are planning to take hormone therapy for at least 5 years.
AmiensAges 18 years+ - NCT06976944RecruitingPhase 2
Pembrolizumab, Paclitaxel, and Bevacizumab for Triple-Negative Breast Cancer
This trial tests a combination of the immunotherapy drug pembrolizumab, the chemotherapy paclitaxel, and possibly the targeted drug bevacizumab for people with triple-negative breast cancer that has returned after treatment. It aims to see if adding bevacizumab improves outcomes for patients whose tumors are PD-L1 positive.
Nagoya, Aichi-kenAges 18 years+ - NCT05862064RecruitingPhase 3
Adding an immune drug and anti-blood-vessel treatment to chemo
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06518382Recruiting
Study of leftover tumor after chemo and trastuzumab
This study looks at leftover breast cancer cells (after chemo and targeted therapy) to find out why some cells resist treatment. It may help doctors better understand how to treat HER2-positive breast cancer in the future.
Milan, LombardyAges 18 years+
Hear when a new Breast Cancer Invasive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer invasive?
- Yes. Clin2 currently lists 717 recruiting breast cancer invasive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer invasive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer invasive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.